Nivolumab (Opdivo®) for adjuvant treatment of oesophageal or gastro-oesophageal junction cancer. HTA ID: 21043

Assessment Status NCPE Assessment Process Complete
HTA ID 21043
Drug Nivolumab
Brand Opdivo®
Indication Nivolumab as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.  
Assessment Process
Rapid review commissioned 21/09/2021
Rapid review completed 20/10/2021
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 28/10/2021
Pre-submission consultation with Applicant 20/12/2021
Full submission received from Applicant 11/05/2022
Preliminary review sent to Applicant 24/10/2022
NCPE assessment re-commenced 21/11/2022
Factual accuracy sent to Applicant 23/01/2023
NCPE assessment re-commenced 30/01/2023
NCPE assessment completed 13/02/2023
NCPE assessment outcome The NCPE recommends that nivolumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.